AI health technology startup Signos expands partnership with Dexcom
Signos combines a wearable glucose monitor with an artificial intelligence-based app.
Source: Signos
Health technology startup Signos announced a $20 million funding round on Wednesday to expand its presence in the GLP-1-based weight loss market and expand its partnership with the medical device giant Dexcom.
Google Ventures, Dexcom and Blue Cross Blue Shield of Alabama invested in this latest round, which includes a new distribution deal to offer Signos’ subscription plans on Dexcom’s direct-to-consumer website.
“Dexcom’s investment truly reflects a shared belief in the future of glucose biosensing beyond diabetes management,” Signos CEO Sharam Fouladgar-Mercer told CNBC. “Your biosensor provides glucose data. We translate that into actual guidelines.”
Signos makes an artificial intelligence-based glucose monitoring system designed to aid in healthy weight loss. It is the first of its kind to be approved by the Food and Drug Administration and approved in 2025.
Dexcom’s standard continuous glucose monitor measures how a user’s lifestyle choices can impact their health in real time, such as their meal choices, sleep and stress levels. From there, the platform provides personalized recommendations for building healthier habits.
“Nobody wants to have a PhD in statistics to understand their own body, and so we’re really helping to translate those glucose insights into actual recommendations, and then pattern recognition is designed to support healthier habits and sustainable weight management,” Fouladgar-Mercer told CNBC.
The startup declined to comment on its valuation after the round.
The new funds will go toward expanding predictive AI capabilities, such as: B. Meal scoring, which uses a user’s data to warn them about whether a particular food could spike their blood sugar levels before consumption.
Fouladgar-Mercer said AI’s real opportunity lies in translating biology into “practical instructions that people can actually use.”
“So you can take a photo of the food and the AI will recognize the essence and figure out the macros and all that, and also the activities, but really it’s about how you do that and determining how your body reacts in real time to give you the feedback that helps you drive behavior change,” he said.
The service is intended either for those who want to supplement their treatment with GLP-1 drugs or as a standalone weight loss system, Fouladgar-Mercer said.
Signos’ new partnership with Dexcom could give the startup greater visibility in the booming weight loss market as demand for expensive GLP-1 drugs increases Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound continues to explode.
According to government data, nearly 74% of Americans are obese or overweight. Estimates of JP Morgan predict that around 25 million Americans will receive a GLP-1 by 2030, more than twice as many patients as in 2025.
Although Fouladgar-Mercer said the company doesn’t disclose metrics on revenue or customer numbers, he said both revenue and user base have increased tenfold in the last six months. He added that “tens of thousands” had participated in clinical trials.
“Just tracking outcomes — like steps or heart rate — is fine, but if we can’t track metabolic effort and response, we can’t help people as effectively as we want,” Fouladgar-Mercer said.
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
